NCT06532071View on ClinicalTrials.gov

Advanced Imaging for Pulmonary Fibrosis

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 21, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Pulmonary Fibrosis
Interventions
DRUG

[68Ga]CBP8

Participants will receive a single intravenous injection of up to 350 MBq of \[68Ga\]CBP8

DRUG

Gadoterate Meglumine

Participants will receive a single intravenous injection of 0.05 mmol/kg gadoterate meglumine during DCE-MRI

Trial Locations (1)

02114

RECRUITING

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Peter Caravan

OTHER